Observational study shows abatacept does not impact drug retention rate in rheumatoid arthritis patients with interstitial lung disease, suggesting treatment efficacy.
In conclusion, the presence of ILD did not affect the retention rate of the drug, suggesting a role for abatacept in the treatment of RA-ILD.
No takes yet. Share an insight, caveat, or question.
Vacchi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: